Showing results (101-110 of 118) with videos related to

Sort By:
Pageof 12
Annals of Surgical Oncology|May 19, 2021
Early Identification of Residual Disease After Neuroendocrine Tumor Resection Using a Liquid Biopsy Multigenomic mRNA Signature (NETest)Irvin M Modlin, Mark Kidd, Kjell Oberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2022
Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine TumorsClare Vesely, Yien Ning Sophia Wong, Alexa Childs, et al.
Endocrine|September 27, 2019
Predictors of antiproliferative effect of lanreotide autogel in advanced gastroenteropancreatic neuroendocrine neoplasmsFaidon-Marios Laskaratos, Eleni Armeni, Heer Shah, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|February 22, 2020
Pancreatic grade 3 neuroendocrine tumors behave similarly to neuroendocrine carcinomas following resection: a multi-center, international appraisal of the WHO 2010 and WHO 2017 staging schema for pancreatic neuroendocrine lesionsPatrick J Worth, Julie Leal, Qian Ding, et al.
British Journal of Cancer|November 26, 2022
Dual [68Ga]DOTATATE and [18F]FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET scoreDavid L Chan, Aimee R Hayes, Ioannis Karfis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 15, 2015
Prognostic Impact of Novel Molecular Subtypes of Small Intestinal Neuroendocrine TumorAnna Karpathakis, Harpreet Dibra, Chistodoulos Pipinikas, et al.
European Journal of Cancer (Oxford, England : 1990)|September 10, 2022
Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial - Prodige 31 REMINET: An FFCD studyCôme Lepage, Jean-Marc Phelip, Astrid Lievre, et al.
Drug Design, Development and Therapy|September 15, 2015
Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analoguesEdward M Wolin, Barbara Jarzab, Barbro Eriksson, et al.
Surgery|May 16, 2022
Clinical features and postoperative survival in patients with sporadic versus multiple endocrine neoplasia type 1-related pancreatic neuroendocrine tumors: An international cohort studyJohn R Bergquist, Omair A Shariq, Amy Y Li, et al.
Neuroendocrinology|August 29, 2018
Evaluation of Clinical Prognostic Factors and Further Delineation of the Effect of Mesenteric Fibrosis on Survival in Advanced Midgut Neuroendocrine TumoursFaidon-Marios Laskaratos, Martin Walker, Dominic Wilkins, et al.
Pageof 12